1 | | 很高，公司是三家全国性麻精药品批发企业之一，并在 15 个省 | | --- | --- | | | 市拥有区域性批发资格，销售网络覆盖全国 31 个省市及自治区， | | | 其中在四川、重庆、贵州、青海、西藏等 5 个地区具有麻精药品 | | | 经销优势。上半年公司麻精药品实现销售 17.36 亿元，同比增加 | | | 19.07%。 | | | 4、公司财务费用下降明显的原因？ | | | 答：公司持续加强对财务费用的管控，今年以来公司融资成 | | | 本下降趋势明显，上半年财务费用同比下降 1.65 亿元，同比降 | | | 幅为 30.35%。财务费用率创五年同期新低，预计未来还有进一 | | | 步下降空间。 | | | 5、公司与通用技术集团内部协同情况如何？ | | | 答：公司加速推进与通用技术集团旗下医疗机构的协同发 | | | 展，报告期内在全国 22 个省开户 104 家，其中 89 家为等级医院， | | | 同时公司在 2025 年 8 月底，与通用健康、中国医药签订战略合 | | | 作协议。三方将整合资源渠道优势，通过优化供应链全流程管理， | | | 实现药 ...

Core Viewpoint - The company Zhongyao Holdings (000950.SZ) has made significant progress in its share repurchase plan, indicating a commitment to enhancing shareholder value while facing challenges in profitability due to industry pressures [1][2]. Group 1: Share Repurchase Progress - As of August 31, Zhongyao Holdings has repurchased 9.313 million shares, accounting for approximately 0.54% of its total share capital, with a total expenditure of about 49.99 million yuan [1]. - The repurchase plan, initiated on July 11, aims to buy back shares worth between 80 million yuan and 100 million yuan, with a maximum price of 6.6 yuan per share [1]. Group 2: Financial Performance - Revenue has shown a steady increase over the past three years, with figures of 67.83 billion yuan in 2022, 78.4 billion yuan in 2023, and projected 80.56 billion yuan in 2024, reflecting successful business expansion [1]. - However, net profit has declined for three consecutive years, with figures of 0.952 billion yuan in 2022, 0.625 billion yuan in 2023, and 0.283 billion yuan in 2024, representing decreases of 5.29%, 34.41%, and 54.69% respectively [2]. Group 3: Recent Developments and Market Expansion - In the first half of 2025, the company achieved a revenue of 41.188 billion yuan, a year-on-year increase of 3.54%, and a net profit of 0.282 billion yuan, up 18.56% [2]. - The company has expanded its market presence, achieving coverage in all 31 provinces and 164 prefecture-level cities, with 65.85% of revenue coming from outside its home base in Chongqing [2]. - The pharmaceutical wholesale business generated over 95% of revenue, amounting to 39.052 billion yuan, while the e-commerce segment saw a transaction volume of approximately 1 billion yuan, growing by 72% [2][3]. Group 4: Retail and Asset Growth - The retail segment reported revenue of 1.947 billion yuan, with over 850 stores across 22 provinces, and has implemented services in 616 stores in response to national policies [3]. - As of mid-2025, total assets reached 67.95 billion yuan, a 2.57% increase year-on-year, while the debt-to-asset ratio improved to 75.61%, down by 0.67 percentage points [3].

证券日报网讯9月2日晚间，重药控股（000950）发布公告称，截至2025年8月31日，公司通过股份回购 专用证券账户以集中竞价交易方式累计回购股份数量为9，313，000股，约占公司总股本的0.5389%。 ...

证券之星消息，9月2日重庆国企改革板块较上一交易日下跌1.11%，*ST惠程领跌。当日上证指数报收于 3858.13，下跌0.45%。深证成指报收于12553.84，下跌2.14%。重庆国企改革板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 600689 | 上海三毛 | 13.79 | 2.99% | 10.02万 | 1.36亿 | | 601158 | 重庆水务 | 4.74 | 0.64% | 15.63万 | 7368.78万 | | 000565 | 渝三峡A | 8.71 | 0.23% | 18.26万 | 1.58 Z | | 601827 | 三峰环境 | 8.54 | 0.00% | 1 5.34万 | 4543.59万 | | 600939 | 車庆建工 | 3.49 | -0.29% | 10.20万 | 3545.34万 | | 000950 | 重药控股 | 5.23 | -0.38% | 22.84万 | 1.19亿 | | 600369 | ...

格隆汇9月2日丨重药控股(000950.SZ)公布，截至2025年8月31日，公司通过股份回购专用证券账户以集 中竞价交易方式累计回购股份数量为9,313,000股，约占公司总股本的0.5389%；最高成交价为5.48元/ 股、最低成交价为5.18元/股，支付总金额为4999.89万元(不含交易费用)。 ...

重药控股股份有限公司 关于回购股份进展的公告 证券代码：000950 证券简称：重药控股 公告编号：2025-065 二、其他说明 公司回购股份的时间、回购股份价格及集中竞价交易的委托时段符合《深圳 证券交易所上市公司自律监管指引第 9 号——回购股份》的相关规定，具体情况 如下： 1.公司未在下列期间回购公司股份： 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 重药控股股份有限公司（以下简称"公司"）分别于 2025 年 7 月 10 日、2025 年 7 月 28 日召开第九届董事会第十五次会议、2025 年第三次临时股东会，审议 通过了《关于回购公司股份的议案》，同意公司使用自有资金及股票回购专项贷 款，通过深圳证券交易所交易系统以集中竞价交易方式回购公司已发行的人民币 普通股（A 股），用于减少公司注册资本。本次用于回购股份的资金总额不低于 人民币 8,000 万元（含本数），不超过人民币 10,000 万元（含本数），回购价格 不超过人民币 6.6 元/股（含本数），回购期限为自股东会审议通过回购股份事项 之日起 12 个月内。具体内容详见公司在巨 ...

Group 1: Company Performance - The company achieved a steady growth in the first half of 2025, with revenue and net profit attributable to shareholders increasing [2] - The medical beauty segment's revenue grew by 21% year-on-year, while the special medical products segment saw a 63% increase, and MAH product revenue surged by 333% [2] - The company's narcotic drug revenue increased by 19.07% year-on-year in the first half of 2025 [2][3] Group 2: Market Position and Collaboration - The company is one of three national narcotic drug wholesalers, with a sales network covering all 31 provinces and autonomous regions in China [3] - Collaboration with the China General Technology Group's medical sector is advancing, with 104 hospitals opened across 22 provinces, 89 of which are graded hospitals [4] Group 3: Market Value Management - The company is focusing on market value management as a key task for the year, utilizing strategies such as information disclosure, cash dividends, and share buybacks [4] - A buyback plan of 80 million to 100 million yuan was approved, with the first buyback executed on August 14 [4] Group 4: Financial Management - Financial expenses have decreased year-on-year, with expectations for further reductions due to enhanced credit and optimized financing structures [5] - The financial expense rate has reached a five-year low, indicating a positive trend in financing costs [5] Group 5: Research and Development - The company is primarily investing in generic drug development, adhering to international standards and focusing on clinically and commercially valuable products [6] - Four products have been approved, with three already in commercial production and sales [7]

Market Overview - The pharmaceutical commercial sector experienced a decline of 2.71% on August 27, with Saily Medical leading the drop [1] - The Shanghai Composite Index closed at 3800.35, down 1.76%, while the Shenzhen Component Index closed at 12295.07, down 1.43% [1] Individual Stock Performance - Saily Medical (603716) closed at 33.15, down 8.93% with a trading volume of 484,700 shares and a transaction value of 1.671 billion [1] - Other notable declines included HeLiang China (603122) down 5.15%, YaoYigou (300937) down 5.10%, and Guofa Shares (600538) down 4.98% [1] - The overall net outflow of main funds from the pharmaceutical commercial sector was 543 million, while retail investors saw a net inflow of 361 million [1] Fund Flow Analysis - Jiuzhoutong (600998) had a main fund net inflow of 11.8 million, accounting for 18.23% of its total [2] - Dacilin (603233) saw a main fund net inflow of 29.97 million, representing 15.70% [2] - The overall trend indicates a mixed sentiment with main funds withdrawing while retail investors are actively buying [2]

重药控股股份有限公司 关于控股股东股权结构拟发生变更的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 2025 年 6 月 19 日，重药控股股份有限公司（以下简称"公司"）披露了《关 于控股股东股权结构拟发生变更的提示性公告》（公告编号：2025-039），公司 控股股东重药医药健康产业有限公司（以下简称"重庆医健"）的股东重庆渝富控 股集团有限公司（以下简称"重庆渝富"）在重庆联合产权交易所集团股份有限公 司（以下简称"重庆联交所"）公开挂牌转让重庆医健 24%股权（以下简称"本次 交易"）。 2025 年 8 月 22 日，公司披露了《关于控股股东股权结构拟发生变更的进展 公告》（公告编号：2025-063），重庆联交所确定本次交易的最终受让方为中国 通用技术（集团）控股有限责任公司（以下简称"通用技术集团"）。交易双方 经协商将按照重庆联交所的相关流程以交易底价 22.06 亿元签订产权交易合同。 证券代码：000950 证券简称：重药控股 公告编号：2025-064 本次转让不会导致重庆医健的控制权发生变更，也不会导致重庆医健持有公 司股份 ...

证券日报网讯重药控股8月26日在互动平台回答投资者提问时表示，公司下属部分公司涉及医疗器械产 品创新，目前部分产品如留置针产品系列、新一代安全采血针系列及AED产品已经实现上市销售，安 全输液器产品已经进入市场准入上市阶段，其他产品处于申报、注册等相关阶段。 （文章来源：证券日报） ...